Open Access

Erratum to: Oral intake of a combination of glucosyl hesperidin and caffeine elicits an antiobesity effect in healthy, moderately obese subjects: a randomized double-blind placebo-controlled trial

  • Tatsuya Ohara1Email author,
  • Koutarou Muroyama1,
  • Yoshihiro Yamamoto1 and
  • Shinji Murosaki1
Nutrition Journal201716:28

DOI: 10.1186/s12937-017-0253-6

Received: 10 May 2017

Accepted: 10 May 2017

Published: 12 May 2017

The original article was published in Nutrition Journal 2016 15:6

Erratum

After publication of this article [1] it was noticed there were errors in the paper regarding the dose and grade of glucosyl hesperidin due to miscommunications.

The composition of glucosyl hesperidin is reported as “500 mg” but this should instead be listed as “470 mg” throughout the article. Additionally, the G-hesperidin should be reported as containing 74% monoglucosyl hesperidin and residual non-glycosylated hesperidin.

Notes

Declarations

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Research & Development Institute, House Wellness Foods Corporation

Reference

  1. Ohara T, Muroyama K, Yamamoto Y, Murosaki S. Oral intake of a combination of glucosyl hesperidin and caffeine elicits an antiobesity effect in healthy, moderately obese subjects: a randomized double-blind placebo-controlled trial. Nutr J. 2016;15:6.View ArticlePubMedPubMed CentralGoogle Scholar

Copyright

© The Author(s). 2017

Advertisement